title: Vecuronium was safely used in a patient with Engelmann's disease without muscle weakness.
authors.forename: Koji
authors.initials: K
authors.lastname: Sato
authors.forename: Maiko
authors.initials: M
authors.lastname: Nakajima
authors.forename: Tetsu
authors.initials: T
authors.lastname: Kimura
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Nishikawa
mesh_terms: D000328:Adult; D003966:Camurati-Engelmann Syndrome / Q000503:physiopathology*; D005260:Female; D006801:Humans; D018908:Muscle Weakness / Q000209:etiology*; D003473:Neuromuscular Nondepolarizing Agents / Q000494:pharmacology*; D014673:Vecuronium Bromide / Q000494:pharmacology*
chemical_list: D003473:Neuromuscular Nondepolarizing Agents; D014673:Vecuronium Bromide